Travere Therapeutics, Inc.
TVTX
$62.14
$0.711.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 74.29% | 90.55% | 92.06% | 74.81% | -15.86% |
| Total Depreciation and Amortization | 26.37% | 57.40% | 39.46% | 33.56% | 21.75% |
| Total Amortization of Deferred Charges | -4.93% | -4.93% | -4.93% | 0.41% | 0.41% |
| Total Other Non-Cash Items | 138.18% | -78.68% | -85.32% | -67.19% | 124.45% |
| Change in Net Operating Assets | 95.51% | 57.71% | 77.79% | 6.41% | 53.37% |
| Cash from Operations | 180.30% | 124.66% | 115.91% | 78.47% | 60.04% |
| Capital Expenditure | 186.59% | -- | -- | -110.34% | -85.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,811.33% | -77.84% | -72.16% | -67.63% | -95.24% |
| Cash from Investing | -1,797.63% | -77.18% | -71.92% | -67.78% | -95.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.79% | -73.91% | -73.48% | 5,283.24% | 6,090.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -774.76% | 0.00% | 0.00% | 10.98% | 19.82% |
| Cash from Financing | 6.03% | -122.96% | -124.00% | 18,394.85% | 57,158.50% |
| Foreign Exchange rate Adjustments | -109.77% | 2,437.50% | 350.93% | 35.73% | 206.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -0.66% | -11.70% | 9,510.03% | 169.11% | 211.09% |